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Background: A Phase III randomized controlled trial investigating the addition of
modulated electro-hyperthermia (mEHT) to chemoradiotherapy for locally advanced
cervical cancer patients is being conducted in South Africa (Human Research Ethics
Committee approval: M1704133; ClincialTrials.gov ID: NCT03332069). Two hundred
and ten participants were randomized and 202 participants were eligible for six month
local disease control evaluation. Screening 18F-FDG PET/CT scans were conducted and
repeated at six months post-treatment. Significant improvement in local control was
reported in the mEHT group and complete metabolic resolution (CMR) of extra-pelvic
disease was noted in some participants. We report on an analysis of the participants
with CMR of disease inside and outside the radiation field.
Method: Participants were included in this analysis if nodes outside the treatment field
(FDG-uptake SUV>2.5) were visualized on pre-treatment scans and if participants were
evaluated by 18F-FDG PET/CT scans at six months post-treatment.
Results: One hundred and eight participants (mEHT: HIV-positive n = 25, HIV-negative
n = 29; Control Group: HIV-positive n = 26, HIV-negative n = 28) were eligible for
analysis. There was a higher CMR of all disease inside and outside the radiation field
in the mEHT Group: n = 13 [24.1%] than the control group: n = 3 [5.6%] (Chi squared,
Fisher’s exact: p = 0.013) with no significant difference in the extra-pelvic response to
treatment between the HIV-positive and -negative participants of each group.
Conclusion: The CMR of disease outside the radiation field at six months
post-treatment provides evidence of an abscopal effect which was significantly
associated with the addition of mEHT to treatment protocols. This finding is important
as the combined synergistic use of radiotherapy with mEHT could broaden the scope of
radiotherapy to include systemic disease.
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INTRODUCTION
The abscopal effect is a systemic response to ionizing radiation
(IR) in which non-irradiated lesions respond after irradiation of
the primary treatment site (1, 2). It is generally accepted that
the abscopal effect is driven by underlying immune mechanisms
which are activated by IR (2–4). One proposed mechanism is the
immunogenic cell death (ICD) caused by IR (3) which requires
the release of damage associated molecular patterns (DAMPs).
These in turn activate dendritic cells and enhance antigen
expression and presentation to the immune system. Ionizing
radiation has also been shown to enhance the functioning of
T-cells (4).
The frequency of reported abscopal effects in the literature is
extremely low with only a handful of published cases per year
(3, 4). In a review, Reynders et al. summarized 23 case reports,
one retrospective study, and 13 pre-clinical papers, from the
1970s to 2014. Only one of these involved a primary squamous
cell carcinoma of the cervix. The patient (age 69 years) was
treated with external beam radiation (EBRT) and brachytherapy
(BT) for locally advanced cervical cancer (LACC) and showed
a complete response of the para-aortic nodes outside of the
radiation field, as well as a complete response of the tumor, on the
post-treatment Abdominal and Pelvic Computed Tomography
(CT) and Pelvic Magnetic Resonance Imaging (MRI) scans (5).
Reynders et al. concluded that the abscopal effect is based on
anti-tumor immunity and was more common in immunogenic
tumor types. Renal cell carcinoma had the most frequently
reported cases of the abscopal effect followed by hepatocellular
carcinoma. The abscopal effect was observed at all ages and with
a variety of radiotherapy protocols. The preclinical data indicates
that some immunomodulatory agents may have potential to act
synergistically with IR to induce a systemic response (4) which
may explain the increase in the number of reported abscopal
effects with the combined treatment of immunotherapies and
IR (6).
The addition of mild hyperthermia to local irradiation has
shown to have immunomodulating effects which may result
in enhanced tumor regression and an abscopal effect when
combined with radiotherapy, as was seen in a liposarcoma patient
treated with hyperthermia and radiotherapy (7). Hyperthermia
may directly activate the immune cells present in the tumor and
its microenvironment (8) and may further enhance the function
of the dendritic cells (9).
Modulated electro-hyperthermia (mEHT) applies amplitude
modulated radiofrequency (13.56 MHz), in a capacitive coupling
set-up to target and heat malignant tissues, sensitizing them to
treatments. The technique exploits the differences in impedance
between the malignant and healthy tissue as well as impedance
matching technology, to selectively deliver an energy to the
malignant tissues. The energy deposition has the net effect of an
increase in the thermal energy, and temperature. The biophysics
are further described in detail in the literature (10–12). Preclinical
research suggests that mEHT combined with immunotherapies is
able to elicit an immune-mediated response (13) which may even
extend to untreated tumors. Vancsik et al. showed that mEHT
induced DAMPs in murine models was followed by an invasion
of antigen presenting cells (APC) and T-cells at the site of the
treated tumor and that when mEHT was administered combined
with a T-cell stimulating agent, APC and T-cell invasion was also
seen in the untreated tumors of the same murine model (14). In
an in vivo study, mEHT combined with dendritic cell therapy
elicited a response to untreated tumors in murine squamous
cell carcinoma (SCCVII) models (15). Ionizing radiation has
shown to increase the expression of immunogenic molecules
such as calreticulin, on the surface of tumor cells and radiation-
induced stress-response leads to the expression of heat shock
protein70 (HSP70) on cell membranes. This Heat Shock Protein
plays an important role in mounting an immune response at
the site when released into the extracellular matrix (16). Yang
et al. reported an increased release of the expressed HSP70 and
increased levels of calreticulin after mEHT, compared to other
heating methods (17).
The safety and heating efficacy of mEHT in cervical cancer
patients has been demonstrated (18–20). Minnaar et al. (19)
reported on local disease control in an ongoing randomized
controlled trial investigating the effects of the addition of mEHT
to chemoradiotherapy (CRT) protocols for the treatment of
LACC. The trial was conducted in a resource-constrained setting
and in high risk patients in South Africa. In the report, 202
participants were eligible for six month local disease-free survival
(LDFS) and local disease control (LDC) (mEHT: n = 101;
Control: n = 101), of which 171 [mEHT: n = 88 (87.1%);
Control: n = 83 (82.2%)], were alive at six months post-
treatment. Participants in the mEHT group had a higher LDC
and complete metabolic response of the tumor (45% and 58%),
than those in the Control Group (24% and 36%), (p = 0.005
and p = 0.003, respectively), and were significantly more likely
to achieve six month LDFS (OR: 0.36, 95% CI: 0.19-0.69; p
= 0.002) (19). During the LDC analysis, it was noted that
some of the participants with extra-pelvic disease present on the
pre-treatment Fluorodeoxyglucose (18F-FDG) Positron Emission
Tomography (PET) /CT scans showed a complete metabolic
resolution (CMR) of disease outside the treatment field on
the post-treatment 18F-FDG PET/CT scans. An analysis of the
subset of patients with extra-pelvic disease visualized on the pre-
treatment 18F-FDGPET/CT scans was subsequently planned.We
present the results of this analysis with the aim of investigating
the possibility of an abscopal effect induced by the addition of
mEHT to CRT in these participants.
METHODS AND MATERIALS
A Randomized controlled trial by Minnaar et al. (19) is being
conducted at the Charlotte Maxeke Johannesburg Academic
Hospital, a public hospital in Johannesburg, South Africa,
by the Radiation Sciences department of the University of
the Witwatersrand. The trial was registered on the South
African National Clinical Trials Register before recruitment
was started (ID:3012) and approval from the Human Research
Ethics Committee was obtained (M704133/M190295). The trial
was registered at ClincialTrials.gov (NCT03332069). Enrolment
began in January 2014 and was closed in November 2017.
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Two hundred and ten participants were randomized to
receive either CRT alone (Control Group) or combined with
mEHT (mEHT Group). Randomization was conducted using
the REDCap on-line computer generated random-sampling tool
with stratification according to HIV status and accounting for age
and FIGO stage. Physicians reporting on the 18F-FDG PET/CT
scans were blinded to treatment allocation and did not interact
with the participants, eliminating the risk of biased reporting.
Eligibility
Eligibility criteria for the trial: Females with International
Federation of Gynecology and Obstetrics (FIGO) (21) stages
IIB to IIIB primary, treatment naïve, histologically confirmed
squamous cell carcinoma of the cervix (staged based on clinical
examination, chest radiography, and a pelvic ultrasound) eligible
for CRT with radical intent; Signed informed consent; >18
years old; Eastern Cooperative Oncology Group (ECOG) score
<2; Creatinine clearance >60 mL/min. Screening evaluations
included full blood count, urea and creatinine levels, liver
function, Human Immunodeficiency Virus (HIV) test; and a CD4
count if necessary. An 18F-FDG PET/CT scan was performed
on eligible participants prior to commencement of therapy, as
a baseline study against which response to treatment could be
measured. Participants with bilateral hydronephrosis, visceral
metastases, or fistulas visualized on the 18F-FDG PET/CT scan
were excluded from the study. HIV-positive patients were
included provided their CD4 count was above 200 cells/µL
and/or they had been on antiretroviral therapy (ART) for more
than six months.
Exclusion Criteria for the trial: Bilateral hydronephrosis;
Second primary malignancy/prior malignancy treated in the
preceding two years; vesicovaginal fistula or rectovaginal fistula
that required a change in treatment protocols; Abnormal liver
function tests; Pregnant or breast feeding; Prior hysterectomy;
Cardiovascular disease (excluding controlled hypertension);
Acute or life-threatening infections or medical conditions;
Contraindications to any of the prescribed treatments.
At the time of this analysis all participants were a minimum
of six months post-treatment and local disease control data
at six months post-treatment was available for all participants
(19). Participants were considered eligible for the sub-analysis
presented in this report if: They met all the trial eligibility criteria;
the pre-treatment 18F-FDG PET/CT scan showed FDG-avid
(SUV > 2.5) nodal disease outside of the pelvic treatment field;
and the participants had a post-treatment 18F-FDGPET/CT scan.
Data Management
Participant data was captured using REDCap (Research
Electronic Data Capture), an online, secure web based
application hosted by the University of the Witwatersrand.
Treatment
All participants were planned to receive 50Gy in 25 fractions
EBRT to the whole pelvis and 24Gy in 3 fractions of high dose
rate (HDR) BT (36Gy equivalent dose in 2Gy fractions for an
alpha-beta ratio of 10; source used: Iridium-192) and two doses
of cisplatin (80 mg/m2) administered 21 days apart (subject to
the participant’s fitness to receive cisplatin), as per institutional
protocol. The goal of RT was for participants to receive a total
dose of 86Gy equivalent by the combination of EBRT and
BT. External beam radiation to the whole pelvis was delivered
using a two dimensional four-field-box technique to include the
tumor and pelvic nodes. Participants were simulated supine. The
superior border of the Anterior-Posterior and Posterior-Anterior
(AP-PA) field was mid-L5. The inferior border was either the
inferior part of the ischial tuberosity or the lowest extension of
the tumor with at least a 2 cm margin, whichever was lower. The
lateral borders were 2 cm beyond the lateral margins of the bony
pelvis. For the lateral fields, the superior and inferior borders
were the same as for the AP-PA fields. The anterior border was
the mid to anterior third of the symphysis pubis and the posterior
border was S2–S3 to include the presacral nodes and possible
tumor extension along the uterosacral ligament.
Modulate electro-hyperthermia (Model: EHY2000+;
Manufacturer: Oncotherm GmbH, Troisdorf, Germany) was
administered twice per week (maximum ten treatments),
at a maximum power of 130W, immediately before EBRT
(maximum 30min from completion of mEHT to completion
of EBRT). Step-up heating protocols were adhered to and
mEHT treatments were administered at least 48 h apart. A 30 cm
diameter round electrode was used and treatment duration was
55min at the final power output, with a minimum planned
energy dose of 360 KJs. Details of the technique are described
elsewhere in the literature (11, 19, 22).
Outcome Measures
Nodes with FDG-avid disease were grouped by region on the pre-
treatment scans: Head and Neck; Thorax; Abdomen (including
the upper pelvis outside of the radiation field); and Pelvis (within
the radiation field). The standard uptake value (SUV) cut-off was
considered to be 2.5 and evaluation of the 18F-FDG PET/CT
scans was based on PERSIST 1.0 Criteria. Tumor response
was classified as Complete Metabolic Response (CMR); Partial
Metabolic Response (PMR); Stable Metabolic Disease (SMD);
Progressive Metabolic Disease (PMD) (23). On the follow-up
scans each region was scored as: no change; resolved nodes; new
nodes. Only the completemetabolic response of all disease (nodes
outside of the radiation field, nodes inside the radiation field, and
the tumor), as visualized on post-treatment 18F-FDG PET/CT
scans, was considered an indicator of the abscopal effect.
Statistics
The frequency of the observed abscopal effect was compared by
group (mEHT or Control) and HIV status (positive or negative)
using a Chi-squared frequency table. Paired t-test was used to
compare the difference in means between groups and logistic
regression was used to test prognostic factors. Two sided p values
are reported and p < 0.05 were considered significant. STATA
13.0 Statistics software program (Stata Corporation, College
Station, Texas, USA), was used to analyze the data.
Ethics
All procedures performed in studies involving human
participants were in accordance with the ethical standards of the
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institutional and/or national research committee (M120477 and
M190295) and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
RESULTS
Characteristics
Two hundred and ten participants were randomized for
treatment, of which 146 [70%] had FDG-avid nodal disease
visualized outside of the radiation field on the pre-treatment
18F-FDG PET/CT scans (mEHT Group: n = 68 [64%]; Control
Group: n= 78 [75%]). One hundred and eight of the participants
with extra pelvic nodal disease survived six months post-
treatment and were eligible for the post-treatment 18F-FDG
PET/CT scans (mEHT Group: n = 54 [79%]; Control Group: n
= 54 [69%]) and were therefore included in this analysis. The
characteristics, including treatment characteristics, of these 108
participants are listed in Table 1. The number of participants
(grouped by treatment group and HIV status) with nodes
visualized in each region on the pre-treatment 18F-FDG PET/CT
scans are shown Figure 1. The median number of weeks between
the final RT treatment and the follow-up 18F-FDG PET/CT scans
was 26.3 in the mEHT Group (Q1: 25.3; Q3: 27.3) and 27 in the
Control Group (Q1: 26; Q3: 29).
Abscopal Effect as Visualized on 18F-FDG
PET/CT
An abscopal response was only considered if all disease, including
the primary tumor, nodes within the radiation field, and all
nodes outside of the radiation field showed a complete metabolic
response (SUV < 2.5) on the six month post-treatment 18F-
FDG PET/CT. Therefore all participants who had an abscopal
effect also showed local disease control (a complete metabolic
response of the tumor and nodes within the pelvic radiation
field). The percentage of participants with complete resolution
of all metabolically active disease on six month post-treatment
18F-FDG PET/CT scans was higher in the mEHT group: n
= 13 [24.1%] than in the control group: n = 3 [5.6%] (Chi-
squared: p = 0.013). There was no significant difference in the
response between the HIV-positive (n = 51) and -negative (n
= 57) groups (HIV-positive: n = 7 [13%]; HIV-negative: n =
9 [16%]; Chi-squared: p = 0.793) with a close to even split
in frequency of abscopal responses observed between the HIV-
positive and -negative participants in each treatment group, as
seen in Figure 2. In a multivariate analysis (confidence interval
[CI] 95%) of age, cisplatin cycles, total radiation dose, and
the number of days between the final radiation treatment and
the follow-up 18F-FDG PET/CT, none of the variables were
indicators of an abscopal effect (Age: OR:1.01, p = 0.692, CI:
0.96-1.07; Cisplatin cycles: OR: 1.20; p = 0.671; CI: 0.51-2.83;
Days to PET/CT: OR: 1.01; p = 0.283; CI: 0.99-1.07; Total RT:
OR: 0.66; p = 0.316; CI: 0.30-1.47). In a univariate analysis, the
CD4 count of participants was also not predictive of an abscopal
effect (OR: 1.00, p = 0.893, CI: 0.997–1.003). In the participants
in whom an abscopal effect was observed, the mean time between
the final radiation and the follow-up 18F-FDG PET/CT was 196
days (range 162–266).
TABLE 1 | Characteristics of participants eligible for analysis of the
abscopal effect.
mEHT Control
54 54
FIGO Staging IIB 25 [46%] 22 [41%]
III 29 [54%] 32 [59%]
Race African 51 [94%] 52 [96%]
Caucasian 1 [2%] 0 [0%]
Other 2 [4%] 2 [4%]
Age [years] Mean 49.3 49.9 p = 0.776
SD 9.98 9.99
Range 30–68 28–70
BMI Mean 28.7 27.0 p = 0.127
SD 5.61 6.01
Range 18–44 15–39
Total RT dose
(EQD2)
Mean 85.7Gy 86Gy p = 0.251
SD 1.65 0
Range 74–86Gy 86Gy
No of Cisplatin
doses
Mean 1.37 1.25 p = 0.321
SD 0.69 0.76
0 doses 5 [9%] 6 [11%]
1 dose 19 [35%] 20 [37%]
2 doses 30 [56%] 28 [52%]
Days between final
RT and PET/CT
Mean 188.2 193.4 p = 0.242
SD 24.05 22.15
Range 54–310 155–266
CD4 count
[cells/µL]
Mean 552.9 543.9 p = 0.089
SD 264.15 276.36
Range 194–1077 134–1524
No of mEHT doses Mean 9.54
SD 1.07
Range 4–10
Average KJ
administered
during mEHT
Mean 382.6 KJ
SD 29.95
Range 259–427 KJ
No significant differences in characteristics and treatment were seen between the two
groups. mEHT, Modulated Electro-Hyperthermia; FIGO, Federation of Gynecology and
Obstetrics; SD, Standard Deviation; BMI, Body Mass Index; RT, Radiation Therapy;
PET/CT, Positron Emission Tomography / Computed Tomography; KJ, Kilojoules.
Follow up
One participant had visceral disease on the pre-treatment 18F-
FDG PET/CT scan: multiple lung nodules (highest SUV in the
left lung of 6.03 and the right lung of 4.38) and a lesion in the
T11 vertebra (SUV 9.71). This participant was in the mEHT
group. The follow-up 18F-FDG PET/CT scan showed no sign
of metabolically active disease. This participant is 18 months
post-treatment and is still disease free. Of the participants who
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FIGURE 1 | Number of patients with nodes visualized by region. The number of participants with nodes visualized in each region is represented graphically, showing a
similar pattern in all participants in each treatment group on the pretreatment 18F-FDG PET/CT. mEHT, Modulated Electro-Hyperthermia; HIV, Human
Immunodeficiency Virus.
FIGURE 2 | Frequency of observed abscopal effect in HIV-positive and
HIV-negative participants in each treatment group. A significant difference
between the frequency of abscopal effect was noted between the mEHT
Group (13 out of 54[24.1%]) and the Control Group (3 out of 54 [5.6%]) (p =
0.013). There was no significant difference in frequency of the observed
abscopal between the HIV-positive and HIV-negative participants. mEHT,
Modulated Electro-Hyperthermia; HIV, Human Immunodeficiency Virus.
showed an abscopal effect, seven out of 13 mEHT participants
and two out of three control participants have reached 2 years
post treatment and are still disease free. Two participants in
the mEHT group and one in the Control group demised before
reaching two years (cause of death: acute renal failure). Four
participants in the mEHT group have not yet reached two years
post treatment (two are 18 months and two are 12 months post-
treatment), however they are still disease free. Table 2 lists all
the sites of FDG avid disease seen in the participants in whom
an abscopal response was observed, the disease-free survival
observed, the viral load, CD4 count, and the HIV status of
the participants.
HIV Status
In order to rule out the effects of HIV on the visualization
of nodes, the cases were reviewed with the intention of
discarding cases which had nodes known to be visualized
in HIV disease. HIV-positive participants with high viral
load levels may have benign hypermetabolic foci visualized
on 18F-FDG PET/CT images, resulting in false positive
interpretations of malignancy (24). Furthermore, Sathekge
et al. showed that the CD4 count of HIV positive participants
was inversely proportional to the FDG uptake in the nodes
(25). During acute HIV infection FDG uptake increases
in the head and neck lymph nodes, in mid stage of HIV
infection hypermetabolism occurs in cervical, axillary, and
inguinal lymph nodes, and an increased FDG uptake occurs
in the colon, mesenteric, and ileocecal lymph nodes during
late HIV disease (24). None of our participants were in
acute (newly diagnosed) or late stage (no Acquired Immune
Deficiency Syndrome-defining illnesses other than cervical
carcinoma) of HIV infection. Four of the participants with
an abscopal response showed increased FDG uptake in the
axillary glands: one was HIV-negative and was therefore
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TABLE 2 | Details of the extra-pelvic disease in participants with an *Abscopal
Effect.
HIV status Days
to PET
No.
ChT
Description of extra-pelvic
disease on pre-treatment
PET/CT
Survival
mEHT group
Pos. (CD4:
863; VL:27)
211 2 Common carotid (SUV 7.5); Para
tracheal (SUV 4.41); Axillary (SUV
5.59)
2YDFS
Pos.
(CD4:194;
VL:<20)
163 1 Bilat. Jugular. digastric (SUV Left:
2.62; Right: 3.34); Axillary (SUV
4.49); Pre- (SUV 2.75) and
Sub-carinal (SUV 3.16);
Retrocrural (SUV 3.47) Bilat. PA
(SUV Left: 2.59; Right: 3.39)
OS: 335
Pos. (CD4:
905; VL:<20)
200 2 Jug. Digastric (SUV 2.6); Hilar
(SUV 2.92)
2YDFS
Pos. (CD4:
845; VL: ND)
190 2 Bilateral supraclav. (SUV Right:
6.04; Left: 2.94)
2YDFS
Pos. (CD4:
456; VL: ND)
192 2 7 Bilat. cervical (highest
SUV4.81); Axillary (SUV 4.24);
Subcarinal (SUV 2.73); CI (SUV
Right: 2.93; Left: 4.73)
2YDFS
Pos. (CD4:
284; VL:196)
182 2 Bilat. Jug. Digastric (SUV Right:
7.42; Left: 2.72); CI (SUV 3.89)
DF at 18 m
Neg. 185 1 Aorto-pulmonary (SUV 2.75) 2YDFS
Neg. 197 1 PA (SUV 4.73) 2YDFS
Neg. 185 2 Cervical (Level IIA SUV 5.67;
Level IIB SUV 3.49)
2YDFS
Neg. 183 0 Bilat. axillary (SUV Left: 2.87;
Right 2.98)
OS: 596
Neg. 193 2 Supraclav. (SUV 7.42);
Paratracheal (SUV 20.38);
Aorto-pulmonary (SUV 14.72);
Bilat. hilar / Peribronchial (SUV
Right 17.86, Left 13.47); Multiple
Pulmonary nodules (SUV Right
6.03, Left 4.38); T11 (SUV 9.71)
DF at 18 m
Neg. 224 1 Coelic axis (SUV 7.93) DF at 12 m
Neg. 189 2 Aorto-pulmonary (SUV 4.1);
Pre-carinal (SUV 3.7)
DF at 12 m
Control
Pos. (CD4:
564; VL: ND)
207 0 PA (SUV 3.35); CI (SUV 4.5 0.9) OS: 483
Neg, 266 2 Aorto-pulmonary (SUV 2.79); PA
(SUV 4.21)
2YDFS
Neg. 183 2 PA (SUV 4.81); Paravertebral
(SUV 6.56)
2YDFS
*An abscopal response was considered if there was complete metabolic resolution of
the extra-pelvic disease and pelvic disease, including the tumor and pelvic nodes, on the
post-treatment 18F-FDG PET/CT scans, with an SUV of <2.5. ChT, Chemotherapy; CI,
Common Iliac; DF, Disease Free; HIV, Human Immunodeficiency Virus; mEHT, Modulated
Electro-Hyperthermia; ND, Not Detectable; OS, Overall Survival; PA, Para aortic; SUV,
Standard Uptake Value; YDFS, Years of Disease Free Survival; VL, Viral Load.
still included, three were HIV-positive and all had increased
FDG uptake in extra-pelvic nodes other than the axillary
nodes. These three participants were therefore still included.
Of the seven HIV-positive participants, one had increased
FDG uptake in the inguinal nodes however several other
extra-pelvic nodes were also visualized and the patient
was included.
DISCUSSION
The CMR of disease outside the radiation field at six months
post-treatment in our sample provides evidence of an abscopal
effect. The frequency of the observed abscopal effect was
significantly associated with the addition of mEHT. This
finding is important as methods to enhance the abscopal effect
could broaden the scope of ionizing radiation from a local
treatment to a systemic and potentially curative modality for
metastatic and systemic disease. The abscopal effect was seen
equally in HIV-positive and -negative participants in the group
treated with mEHT. This suggests that the potentiation of the
systemic, immune-mediated response to IR was not inhibited
by HIV-infection and could still be possible in such high
risk patients.
Reynders et al. reported that the median time to achieve
an abscopal response was five months, ranging from 1 to 24
months (4). In our study we assessed the abscopal effect as part
of the disease response at six months, which corresponds to the
findings by Reynders et al. In their review Reynders et al. report
on patients who had received multiple fractions of radiotherapy
followed by a reduction in size/metabolic activity of a non-
irradiated lesion (partial response). In our report we present
only participants who showed a complete metabolic response
of all disease, including the primary tumor. This strengthens
the probability of an abscopal response in our participants.
Reynders et al. excluded papers in which systemic cytotoxic
drugs were administered (4). We have included participants
who were treated with cisplatin as a radiosensitiser, however
the administration of cisplatin to participants in the mEHT
Group and Control group was evenly matched suggesting that
the difference between responses in the two groups was not the
due to the cisplatin and is associated with the addition of mEHT.
Furthermore cisplatin was not a predictor of an abscopal effect in
our sample.
The rarity of the abscopal effect documented in the literature
suggests that the abscopal effect alone is unlikely to impact
clinical regimes and influence treatment choices (3). Considering
their immune components, the combination of radiotherapy
with immunotherapies and mEHT may provide an opportunity
to boost abscopal response rates. Reynders et al. reported
on four case reports of the abscopal effect using Ipilimumab
(one in adenocarcinoma of the lung and three in melanoma
patients), one using BCG-vaccination (adenocarcinoma of the
lung) combined with IR, and one retrospective study in which 11
out of 21 melanoma patients treated with Ipilimumab followed
by palliative radiotherapy showed an abscopal response (4).
The increase in use of immunotherapies combined with IR has
resulted in an increase in the reports of abscopal effects. At least
ten trials have been registered on ClincialTrials.gov to investigate
the effects, including the abscopal effect, of immunotherapies
combined with IR. The lack of reliable biomarkers to predict
and confirm the presence of an abscopal effect may impact
Frontiers in Oncology | www.frontiersin.org 6 March 2020 | Volume 10 | Article 376
Minnaar et al. Modulated Electro-hyperthermia Potentiates Abscopal Effect
on the future optimization of protocols to induce an abscopal
effect. An important future field of investigation is therefore
the development of biomarkers which can reliably predict and
quantify the presence of an abscopal effect.
Preclinical data on the synergistic effects of
immunomodulating agents and mEHT with IR, as well as
case reports, and the results of this study, provide strong support
for the development of trials on the combined use of IR with
mEHT and immunotherapies. Positive results in such trials
would broaden the scope of ionizing radiation from local
or palliative treatment to a potentially curative modality in
metastatic and systemic disease.
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